Continuous subcutaneous insulin infusion vs. multiple daily injections

Saša Radenković, Milica Pešić, Milena Velojić Golubović, Dragan Dimić, Danijela Radojković, Vojislav Ćirić 1 , and Radivoj Kocić
  • 1 Clinic for Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center Niš, Bulevar Dr Zorana Djindjica 48, 18000, Niš, Serbia
  • 2 Department for Internal Medicine, Faculty of Medicine, University of Niš, Bulevar Dr Zorana Djindjica 81, 18000, Niš, Serbia

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986

  • [2] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837–853

  • [3] Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739–746

  • [4] Pickup J, Keen H. Continuous subcutaneous insulin infusion 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593–598

  • [5] Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705–708

  • [6] Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583–588

  • [7] Zinman B: Insulin pump therapy and rapid acting insulin: what have we learned? Int J Clin Pract 2001;123:47–50

  • [8] Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006;23:285–292

  • [9] Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004;21:1213–1220

  • [10] Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal oncedaily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170–1176

  • [11] Harmel AP, Mathur R. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 2004;27:272–273

  • [12] Davidson P, Hebblewhite H, Steed R, Bode B. A deductive framework to aid in understanding CSII parameters: carbohydrate-to-insulin ratio (CIR) and correction factor (CF). Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13–17, 2003; New Orleans, Louisiana. Abstract 443-P

  • [13] Hannaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000;23:1232–1235

  • [14] Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554–1558

  • [15] Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31Suppl 2:S140–S145

  • [16] Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine 2008;25:765–774

  • [17] Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: The impact of baseline A1c. Diabetes Care 2004:27:2590–2596

  • [18] Nimri R, Weintrob N, Benzaquen H, Ofan R, Fayman G, Phillip M. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006;117:2126–2131

  • [19] Fahlén M, Eliasson B, Oden A. Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabetic Medicine 2005;22:382–386

  • [20] Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079–1087

  • [21] Karagianni P, Sampanis Ch, Katsoulis Ch, Miserlis G, Polyzos S, Zografou I, et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Hippokratia 2009;13:93–96

  • [22] Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, et al. Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children with Type 1 Diabetes: A Randomized Open Crossover Trial. Pediatrics 2003;112:559–564

  • [23] The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711–1721


Journal + Issues